Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple mineral boost pain relief for jaw sufferers?

NCT ID NCT07390851

Symptom relief Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether adding magnesium sulfate to a standard lidocaine injection can better relieve pain and improve muscle function in people with myofascial pain dysfunction syndrome (chronic jaw muscle pain). About 28 adults with active trigger points will receive either lidocaine alone or lidocaine plus magnesium. Pain and muscle activity will be measured using a pain scale and muscle sensors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 28 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 and 70 years. 2. Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS). 3. Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius). 4. Pain duration ≥ 3 months. 5. Pain intensity ≥ 4 on the Visual Analog Scale (VAS). 6. Noprior trigger point injection in the affected area within the past 3 months. 7. Ability and willingness to provide informed consent. 8. Compliance with study visits and procedures Exclusion Criteria: 1. Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents. 2. Current use of anticoagulants or history of bleeding disorders. 3. Systemic or local infection at or near the injection site. 4. History of fibromyalgia, central pain syndromes, or cancer-related pain. 5. Major psychiatric illnesses (e.g., schizophrenia, severe depression). 6. Recent surgery or trauma to the head, neck, or upper back (\<6 months). 7. Use of analgesics (NSAIDs, opioids) within 5 days before intervention. 8. Severe systemic diseases:- Uncontrolled diabetes mellitus- Liver or kidney failure- Severe cardiovascular conditions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myofascial pain dysfunction syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fibromyalgia myofascial pain syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myofascial pain dysfunction syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of oral and dental medicine, cairo university

    RECRUITING

    Giza, Giza Governorate, 12613, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.